Our Science
Proprietary medicines engineered to unlock the brain’s own healing ability.
Science
Introduction
The human brain has a remarkable ability to heal and adapt. EPIK’s medicines are designed to activate that healing process in people whose brains have been disrupted by mental illness, addiction, or chronic pain.
Our platform is built on ketamine — a medicine that has been used safely in clinical settings for decades. We have taken ketamine’s core therapeutic benefits and engineered a new generation of formulations that we believe are more effective and less addictive, and designed primarily for home use.
THREE KEY POINTS
How Our Medicines Work
What We Target
Our medicines work by interacting with specific receptors in the brain that control how we process pain, regulate mood, and form habits. When these receptors are disrupted — by trauma, chronic pain, or addiction — the brain gets stuck in harmful patterns. Our formulations are expected to reset those patterns by triggering the brain’s natural repair mechanisms.
What Makes Our Formulations Different?
Most ketamine treatments use ketamine alone. EPIK combines ketamine with other carefully selected, FDA-recognized ingredients that amplify its therapeutic effects. Each ingredient is chosen because it helps the brain heal more completely and more quickly. We believe the result is a formulation more effective with less side effects than standalone ketamine.
How Patients Take It?
EPIK is developing five or more proprietary delivery methods to give patients greater flexibility and convenience. These include multiple sublingual (under-the-tongue) formulations, topical application, and intravenous options. Most of our delivery formats are designed for at-home use without requiring clinic supervision — making treatment more accessible and affordable for patients everywhere.
LabCorp Validation
Our formulations have been developed in partnership with LabCorp’s elite drug development division. This partnership validates the science behind our approach and gives us access to one of the most experienced drug development teams in the country. LabCorp’s accepted programs have a greater than 85% FDA approval success rate.
Conditions We Are Targeting
Each condition below is a separate development program with its own timeline and regulatory strategy:
• Depression
• Anxiety disorders
• Opioid use disorder
• Chronic and severe pain
regulatory path
Why Our Approach is Lower Risk
Compared to other companies in the psychedelic medicine space, EPIK’s regulatory path is significantly simpler:
• All of our ingredients are already FDA-recognized — we are not asking the FDA to approve a completely new substance
• We plan to use an existing expedited FDA approval (orphan drug, fastrack, breakthrough therapy, 505b2) that allows us to build on decades of ketamine safety data — saving years of clinical work